AOD9604 2mg For Bodybuilding CAS:221231-10-3

    What is AOD9604? Beyond the "GH Fragment" Label

    ●Origin: Synthesized in the 1990s by Australian researchers at Monash University, AOD9604 (AOD standing for "Anti-Obesity Drug") is a modified C-terminal fragment of human Growth Hormone (hGH), specifically encompassing amino acids 177-191.

    ●Core Concept: The hypothesis was that this specific fragment retained the fat-mobilizing (lipolytic) properties of full-length GH, but without the growth-promoting (mitogenic) and insulin-disrupting effects associated with the N-terminal portion. This promised targeted fat loss without the drawbacks of GH therapy.

    ●Key Distinction: It is NOT simply a "piece of GH" acting identically. Its modification (tyrosine substitution) aimed to enhance stability and receptor interaction compared to the natural fragment. Think of it as a highly specialized tool designed for one job (fat metabolism), derived from the blueprint of a multi-tool (full GH).

    ●Mechanism of Action (Novel Insight): While often simplistically linked to GH receptors, AOD9604's action is more nuanced:

    ○Direct Lipolytic Stimulation: It binds to specific sites on fat cells (adipocytes), potentially distinct from the classical GH receptor, triggering a cascade involving cyclic AMP (cAMP) and Protein Kinase A (PKA). This activates Hormone-Sensitive Lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids (FFAs) for energy.

    ○Inhibition of Lipogenesis: Evidence suggests it may also suppress pathways involved in fat storage (like those involving the enzyme acetyl-CoA carboxylase), creating a dual-action effect – releasing existing fat while hindering new fat creation.

    ○Metabolic Rate Modulation: Some studies indicate a potential increase in basal metabolic rate (BMR), though the mechanism here is less clear than direct lipolysis.

    ○Crucially Lacking: It does not significantly stimulate IGF-1 production, muscle growth (hypertrophy), or cause hyperglycemia in the way full GH or its N-terminal fragments can. This is its defining feature and theoretical advantage.

    ●Selectivity: This targeted action on fat metabolism is its hallmark feature, theoretically separating fat loss from other systemic GH effects.

    ●Stability: The tyrosine modification improves stability over the natural fragment, but it's still a peptide requiring careful handling (refrigeration, reconstitution with bacteriostatic water).

    ●Primary Stated Goal: Enhanced Fat Loss / Cutting: This is the core rationale. Bodybuilders use it during cutting phases aiming to:

    ○Reduce subcutaneous fat (especially stubborn areas) while preserving lean muscle mass.

    ○Achieve a leaner, more defined physique without drastic calorie cuts that risk muscle loss.

    ○Potentially see improved muscle definition due to reduced fat covering.

    ●Secondary Applications (Less Supported, Anecdotal):

    ○Improved Recovery: Some users report faster recovery between workouts. Theoretically, this could stem from increased nutrient partitioning (shuttling energy towards repair) or reduced inflammation, but robust evidence is lacking. This is not its primary mechanism like BPC-157 or TB-500.

    ○Injury Healing Support: Similar to recovery, any benefit is likely indirect (improved metabolic environment, potential anti-inflammatory whispers in studies) and vastly overshadowed by dedicated healing peptides. It is not a primary healing agent.

    ○"Recomp" Potential: The dream of losing fat while gaining muscle simultaneously. AOD9604 might contribute to a recomp effect when combined with intense resistance training and precise nutrition, primarily by facilitating fat loss while not interfering with muscle growth signals. It is not an anabolic agent driving muscle gain itself.

    ●Potential Benefits (Based on Theory & Limited Evidence):

    ○Targeted Fat Reduction: Especially appealing for stubborn fat deposits resistant to diet/exercise.

    ○Muscle Sparing: By not disrupting insulin sensitivity significantly and promoting fat as fuel, it may help preserve muscle during caloric deficit.

    ○Minimal Side Effect Profile (Compared to GH/Anabolics): When used correctly, reported side effects are generally mild (see below). No androgenic effects, no estrogenic conversion, no liver toxicity.

    ○No Significant Impact on Blood Sugar: A key differentiator from full GH.

    ○Rapid Clearance: Short half-life minimizes accumulation risk.

    ●The Reality Check & Controversy:

    ○Human Clinical Trial Failure: Crucially, the most significant human obesity trial (Phase IIb) failed to show statistically significant weight loss compared to placebo. This casts immense doubt on its efficacy at the doses studied.

    ○Anecdotal Reports are Mixed: Bodybuilding forums show significant divergence – some users swear by it for stubborn fat, others report zero noticeable effects. Placebo effect is a major confounder.

    ○"Spot Reduction" Myth: While it may have greater effect on metabolically active stubborn fat, systemic fat loss still follows overall energy deficit rules. It won't magically melt only belly fat while ignoring other areas.

    ○Cost vs. Benefit: Given its price and the equivocal evidence, the cost-to-benefit ratio is often questioned compared to proven strategies (diet optimization, proven fat burners like caffeine/yohimbine, or even GH fragments like HGH Frag 176-191).

    ●Typical Bodybuilding Dosage Range: 300mcg to 500mcg per day is the most commonly cited range. The 2mg vial allows for multiple doses (e.g., 4 doses of 500mcg).

    ●Frequency: Due to its short half-life (see below), it is typically administered once daily, often subcutaneously (SubQ). Some protocols suggest splitting the dose (e.g., 250mcg twice daily), but evidence for superiority is lacking. Timing (morning, pre-workout, pre-bed) is highly debated with little consensus.

    ●Reconstitution: The 2mg lyophilized powder must be reconstituted with Bacteriostatic Water (BAC Water). Concentration depends on desired dose volume (e.g., 1ml BAC Water yields 500mcg per 25 unit mark on an insulin syringe).

    ●Crucial Considerations:

    ○No Official Guidance: These doses and protocols are derived solely from broscience and anecdote. There is no established safe or effective human dose.

    ○Start Low: If experimenting, begin at the lower end (e.g., 250mcg/day) to assess tolerance.

    ○Purity is Paramount: Sourcing from unreliable research chemical suppliers carries significant risks of contamination or under-dosing.

    ●Common Cycles: Typically range from 4 weeks to 12 weeks.

    ●Rationale:

    ○Tolerance: Theoretically, continuous stimulation of fat cell receptors might lead to diminished response over time (tachyphylaxis), though evidence is weak. Shorter cycles aim to avoid this.

    ○Cost: Longer cycles become prohibitively expensive.

    ○Lack of Long-Term Data: Safety beyond a few months is completely unknown.

    ●Novel Perspective: Given the lack of strong evidence for tachyphylaxis and the failed long-term obesity trial, the optimal cycle length is entirely speculative. Short cycles (4-8 weeks) aligned with intense cutting phases are pragmatic but not scientifically validated.

    ●Estimated Half-Life: Approximately 30 to 45 minutes. This is very short.

    ●Implications:

    ○Rapid Clearance: Eliminates quickly from the bloodstream, minimizing long-term systemic exposure or accumulation risk.

    ○Frequent Dosing Not Necessary?: Despite the short half-life, the metabolic effects triggered by its receptor binding (like cAMP activation) likely persist for hours, explaining why once-daily dosing is standard. Twice-daily dosing offers no proven kinetic advantage.

    ○No Long Tail: Unlike compounds with long half-lives, effects cease rapidly after discontinuation.

    ●Critical Clarification: AOD9604 does NOT suppress the Hypothalamic-Pituitary-Testicular (HPT) axis.

    ●Mechanism: It does not mimic luteinizing hormone (LH), follicle-stimulating hormone (FSH), or testosterone. It does not interact with estrogen or androgen receptors. Its action is targeted primarily at fat cell metabolism.

    ●Conclusion: PCT is NOT required or beneficial after an AOD9604 cycle. It does not cause the shutdown associated with anabolic steroids or SARMs. Any suggestion otherwise is fundamentally misunderstanding its pharmacology.

    ●Reported Side Effects (Usually Mild/Transient):

    ○Increased hunger (paradoxical, given its fat-loss aim).

    ○Mild headache.

    ○Flushing.

    ○Temporary numbness/tingling at injection site.

    ○Very rare reports of tiredness.

    ●Lack of Long-Term Safety Data: This is the paramount concern. The failed Phase IIb trial means long-term human safety profiles are non-existent. Chronic effects on metabolism, potential impacts on other tissues with GH receptors (though selective, not guaranteed), or unforeseen consequences are unknown.

    ●Legality & Sourcing: Sold strictly as a research chemical (RC), not for human consumption. Legal status varies, but it is not an approved drug. Sourcing carries risks of contamination, mislabeling, and adulteration. Injection inherently carries risks (infection, abscess).

Trade names	Fragment 177-191; AOD 9604 acetate; peptides AOD9604; Peptide HGH 176-191; polypeptide AOD 9604; HGH frag 176-191 Oxidized
CAS	221231-10-3
Molar mass	1815.1
Formula	C78H123N23O23S2
Purity	Above 98%
Apprarance	2mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    AOD9604 (2mg) represents a fascinating concept in metabolic manipulation: harnessing the fat-burning signal of GH without its anabolic or diabetogenic baggage. Its theoretical benefits for bodybuilding – targeted fat loss, muscle sparing, clean profile – are compelling. However, the stark reality of its failed pivotal human trial casts a long shadow over its efficacy. While anecdotal reports persist, particularly for stubborn fat, these are confounded by placebo, diet, exercise, and often concurrent substance use.

    Its short half-life and lack of HPT axis suppression simplify dosing and eliminate PCT concerns. Side effects are generally mild, but the complete absence of long-term safety data in humans is a critical, non-negotiable risk factor. The cost, legal gray area, and sourcing risks further complicate its profile.

    For the bodybuilder considering AOD9604, it must be viewed as a highly speculative, expensive experiment with unproven benefits and unknown long-term risks. It is not a magic bullet for fat loss or a substitute for foundational diet, training, and proven strategies. Any use should be approached with extreme caution, realistic expectations (preparation for no noticeable effect), and full acknowledgment of the significant gaps between its theoretical promise and the current scientific and practical reality. The novel insight is that its primary value today lies more as a research subject illuminating fat metabolism pathways than as a reliably effective bodybuilding tool.

Hot Tags: aod9604 2mg for bodybuilding cas:221231-10-3, China aod9604 2mg for bodybuilding cas:221231-10-3 manufacturers, suppliers, factory